Genelux Corporation Common Stock (GNLX)

Genelux Corporation Common Stock (GNLX) is a Biotechnology company in the Healthcare sector listed on the NASDAQ.

As of Oct 23, 2026: market cap $114M; returns 1 day +1.0%, 1 week -17.4%, 1 year -74.1%.

Genelux Corporation is a late clinical-stage biopharmaceutical company focused on developing next-generation oncolytic viral immunotherapies for patients with aggressive and difficult-to-treat solid tumors. The company currently generates minimal to no revenue, as its lead product candidates are still in development.

Groups GNLX belongs to

• Oncology
• Clinical Stage Biopharma
• Immunotherapy
• Biotechnology
• Biopharmaceutical
• Clinical Stage
• Cancer Therapeutics
• Healthcare
• Ovarian Cancer
• Clinical Stage Biotech
• Life Sciences

GNLX financial model: income statement, cash flow and balance sheet